- Home
- BTI vs SNY Comparison
BTI vs SNY Comparison
Compare BTI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTI
- SNY
- Stock Information
- Founded
- BTI 1902
- SNY 1994
- Country
- BTI United Kingdom
- SNY France
- Employees
- BTI N/A
- SNY N/A
- Industry
- BTI Medicinal Chemicals and Botanical Products
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- BTI Health Care
- SNY Health Care
- Exchange
- BTI Nasdaq
- SNY Nasdaq
- Market Cap
- BTI 113.4B
- SNY 116.1B
- IPO Year
- BTI N/A
- SNY N/A
- Fundamental
- Price
- BTI $55.87
- SNY $52.10
- Analyst Decision
- BTI Strong Buy
- SNY Buy
- Analyst Count
- BTI 3
- SNY 4
- Target Price
- BTI $62.00
- SNY $61.50
- AVG Volume (30 Days)
- BTI 3.9M
- SNY 2.5M
- Earning Date
- BTI 02-12-2026
- SNY 10-24-2025
- Dividend Yield
- BTI 5.45%
- SNY 3.08%
- EPS Growth
- BTI N/A
- SNY 105.93
- EPS
- BTI 1.89
- SNY 8.67
- Revenue
- BTI $35,067,817,512.00
- SNY $53,890,648,839.00
- Revenue This Year
- BTI $0.01
- SNY $2.37
- Revenue Next Year
- BTI $2.95
- SNY $6.51
- P/E Ratio
- BTI $29.59
- SNY $5.99
- Revenue Growth
- BTI N/A
- SNY N/A
- 52 Week Low
- BTI $34.82
- SNY $44.62
- 52 Week High
- BTI $59.29
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- BTI 70.83
- SNY 63.80
- Support Level
- BTI $50.84
- SNY $48.55
- Resistance Level
- BTI $56.24
- SNY $51.64
- Average True Range (ATR)
- BTI 0.61
- SNY 0.73
- MACD
- BTI 0.54
- SNY 0.08
- Stochastic Oscillator
- BTI 93.24
- SNY 90.76
About BTI British American Tobacco Industries p.l.c. ADR
The third-largest tobacco company by volume, British American Tobacco sold 518 billion cigarettes in 2024. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the US. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 22.9% stake in ITC limited, the largest Indian cigarette company.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.